Recruiting Hidradenitis Suppurativa Studies in Sacramento
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under ar...
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis sup...
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS)....
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
The primary purpose of the study is evaluate the effect of brensocatib compared with placebo....
Descemet Endothelial Thickness Comparison Trial I
Descemet Endothelial Thickness Comparison Trial (DETECT) I is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 160 patients in a 2x2 factorial design. The purpose...
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesi...
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. The purpose of th...
Descemet Endothelial Thickness Comparison Trial II
Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DM...
About Hidradenitis Suppurativa Clinical Trials in Sacramento
Hidradenitis suppurativa is a chronic skin condition causing painful lumps under the skin, typically in areas where skin rubs together. It can lead to tunnels under the skin and scarring. Treatment includes antibiotics, biologics, and surgical interventions.
There are currently 8 hidradenitis suppurativa clinical trials recruiting participants in Sacramento, CALIFORNIA. These studies are seeking a combined 2,688 participants. Research is being sponsored by AbbVie, Novartis Pharmaceuticals, Avalo Therapeutics, Inc. and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Hidradenitis Suppurativa Clinical Trials in Sacramento — FAQ
Are there hidradenitis suppurativa clinical trials in Sacramento?
Yes, there are 8 hidradenitis suppurativa clinical trials currently recruiting in Sacramento, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Sacramento?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Sacramento research site will contact you about next steps.
Are clinical trials in Sacramento free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Sacramento studies also compensate for your time and travel.
What hidradenitis suppurativa treatments are being tested?
The 8 active trials in Sacramento are testing new therapies including novel drugs, biologics, and treatment approaches for hidradenitis suppurativa.
Data updated March 2, 2026 from ClinicalTrials.gov